Xanthon Wins Patent in Australia for Biomolecule Detection Technology | GenomeWeb

NEW YORK, Oct. 24 - Xanthon has won a patent in Australia that covers a method of directly detecting biomolecules through a “transition-metal-mediated, catalytic, oxidation-reduction reaction,” the company said on Wednesday.

The patent, numbered 724,600 and entitled "Electrochemical detection of nucleic acid hybridization," is owned by the University of North Carolina at Chapel Hill and is exclusively licensed to Xanthon on a worldwide basis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.